ATE289815T1 - Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie - Google Patents

Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie

Info

Publication number
ATE289815T1
ATE289815T1 AT96945220T AT96945220T ATE289815T1 AT E289815 T1 ATE289815 T1 AT E289815T1 AT 96945220 T AT96945220 T AT 96945220T AT 96945220 T AT96945220 T AT 96945220T AT E289815 T1 ATE289815 T1 AT E289815T1
Authority
AT
Austria
Prior art keywords
glaucoma
medication
preparing
treatment
sulfonyl compounds
Prior art date
Application number
AT96945220T
Other languages
English (en)
Inventor
Michael A Kapin
Louis M Desantis Jr
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Application granted granted Critical
Publication of ATE289815T1 publication Critical patent/ATE289815T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT96945220T 1995-12-21 1996-12-20 Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie ATE289815T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US935195P 1995-12-21 1995-12-21
PCT/US1996/020197 WO1997023222A1 (en) 1995-12-21 1996-12-20 Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia

Publications (1)

Publication Number Publication Date
ATE289815T1 true ATE289815T1 (de) 2005-03-15

Family

ID=21737108

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96945220T ATE289815T1 (de) 1995-12-21 1996-12-20 Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie

Country Status (14)

Country Link
US (2) US6271224B1 (de)
EP (1) EP0868186B1 (de)
JP (1) JP3719609B2 (de)
KR (1) KR100452715B1 (de)
CN (1) CN1155383C (de)
AT (1) ATE289815T1 (de)
AU (1) AU720326B2 (de)
DE (1) DE69634414T2 (de)
ES (1) ES2238702T3 (de)
HK (1) HK1015691A1 (de)
MX (1) MX9805033A (de)
PT (1) PT868186E (de)
TW (1) TW534814B (de)
WO (1) WO1997023222A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100444843C (zh) * 1998-08-10 2008-12-24 旭化成制药株式会社 法舒地尔盐酸盐缓释口服制剂
CA2307285C (en) 1998-08-17 2009-03-31 Senju Pharmaceutical Co., Ltd. Agent for prophylaxis and treatment of glaucoma
WO2000057914A1 (en) * 1999-03-25 2000-10-05 Santen Pharmaceutical Co., Ltd. Ocular tension-lowering agents
EP1177796B1 (de) 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Arzneimittel zur präventiven oder therapeutische Behandlung von Lebererkrankungen
EP1064944A1 (de) * 1999-06-25 2001-01-03 Schering Aktiengesellschaft Protein-Kinase N Hemmer enthaltend Fasudil
US7109208B2 (en) 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
EP1474109B1 (de) 2001-12-21 2010-08-25 Alcon, Inc. Verwendung von synthetischen anorganischen nanoteilchen als träger für augenmedikamente
EP1471925A2 (de) * 2001-12-21 2004-11-03 Alcon, Inc. Anorganische nanopartikel zur modifizierung der viskosität und physikalischer eigenschaften von ophthalmischen und ohrenheilkundigen zusammensetzungen
AU2003257588A1 (en) * 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
AU2003280812A1 (en) * 2002-11-18 2004-06-15 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER
EP1550446A1 (de) * 2003-11-14 2005-07-06 Switch Biotech Aktiengesellschaft Verwendung von 1-(5-Isochinolinsulfonyl)homopiperazin zur Behandlung und Vorbeugung von Hypopigmentstörungen
WO2004096222A1 (en) * 2003-04-30 2004-11-11 Switch Biotech Ag Use of 1-(5-isoquinolinesulfonyl)homopiperazine, its active metabolites, isomers and salts for treating and preventing hypopigmentary disorders
EP1679308B1 (de) 2003-10-15 2013-07-24 Ube Industries, Ltd. Neues indazolderivat
CA2548146A1 (en) * 2003-12-22 2005-07-14 Alcon, Inc. Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
MXPA06006980A (es) * 2003-12-22 2006-12-14 Alcon Inc Agentes para tratamiento de retinopatia glaucomatosa y neuropatia optica.
CN1929847B (zh) * 2004-03-16 2011-01-19 旭化成制药株式会社 含有法舒地尔的制剂及改善其稳定性的方法
US20060115870A1 (en) * 2004-03-30 2006-06-01 Alcon, Inc. High throughput assay for human Rho kinase activity
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
US20060142270A1 (en) * 2004-12-23 2006-06-29 Kowa Co., Ltd. Preventing or treating agent for glaucoma
TWI367098B (en) * 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
MX2007007797A (es) * 2004-12-27 2007-08-23 Alcon Inc Analogo de aminopirazina para tratar glaucoma y otras enfermedades mediadas por rho cinasa.
KR101333970B1 (ko) * 2005-05-19 2013-11-27 코와 가부시키가이샤 녹내장 예방 또는 치료제
CA2621181C (en) 2005-08-30 2011-04-19 Asahi Kasei Pharma Corporation 5-isoquinolinesulfonamide compounds
CN100367967C (zh) * 2005-12-12 2008-02-13 天津红日药业股份有限公司 一种盐酸法舒地尔口服制剂
MX2008008328A (es) * 2005-12-22 2008-09-15 Alcon Res Ltd (indazol-5-il)-pirazinas y (1,3-dihidro-indol-2-ona)-pirazinas para tratar enfermedades y condiciones mediadas con rho cinasa.
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
RU2008152065A (ru) 2006-06-08 2010-07-20 Убе Индастриз, Лтд (Jp) Новое производное имидазола со спироциклической структурой в боковой цепи
US20080064681A1 (en) * 2006-09-11 2008-03-13 Hiroyoshi Hidaka Therapeutic agent for treating glaucoma
AR064420A1 (es) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
US8415372B2 (en) * 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative
ES2396795T3 (es) * 2007-07-02 2013-02-27 Asahi Kasei Pharma Corporation Compuesto de sulfonamida y cirstal del mismo
US20120101167A1 (en) * 2010-10-25 2012-04-26 Langham Maurice E Treatment of ocular and cerebral ischemia
CN102028694B (zh) * 2010-11-12 2012-03-14 天津红日药业股份有限公司 法舒地尔经眼部给药用于制备治疗青光眼药物中的应用
US8883792B2 (en) 2010-12-22 2014-11-11 D. Western Therapeutics Institute, Inc. Substituted isoquinoline derivative
ES2684351T3 (es) 2011-02-04 2018-10-02 Kowa Co., Ltd. Terapia farmacológica para prevenir o tratar glaucoma
CN102138895B (zh) * 2011-03-30 2013-01-23 天津红日药业股份有限公司 一种含盐酸法舒地尔的滴眼剂及其制备
WO2012135465A2 (en) * 2011-04-01 2012-10-04 Indiana University Research And Technology Corporation Treatment of glaucoma
JP2013035802A (ja) * 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
JP2013129605A (ja) * 2011-12-20 2013-07-04 Kowa Co 緑内障治療薬を含有する安定なフィルム製剤
JP2013129604A (ja) * 2011-12-20 2013-07-04 Kowa Co 緑内障治療薬を含有する徐放性フィルム製剤
EP2628482A1 (de) 2012-02-17 2013-08-21 Academisch Medisch Centrum Rho Kinase Inhibitoren in der Verwendung zur Behandlung von Neuroblastoma
JP5557408B1 (ja) * 2013-04-24 2014-07-23 国立大学法人九州大学 眼底疾患治療剤
JP6794454B2 (ja) * 2015-09-25 2020-12-02 オコジェン、インコーポレイテッドＯｋｏｇｅｎ， Ｉｎｃ． ランピルナーゼおよび／またはアンフィナーゼを使用するウイルス性結膜炎の処置
US12048761B2 (en) 2015-10-13 2024-07-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
EP4088719A1 (de) * 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von kapillarer nichtperfusion der netzhaut
US11739326B2 (en) 2017-11-14 2023-08-29 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
WO2019124488A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
AU2021331624A1 (en) * 2020-08-31 2023-05-04 Visus Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases
TW202237083A (zh) 2021-01-11 2022-10-01 美商英塞特公司 包含ｊａｋ路徑抑制劑及ｒｏｃｋ抑制劑之組合療法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456757A (en) 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
NZ200429A (en) 1981-04-30 1984-10-19 Smith & Nephew Ass Applicator for placing pharmaceutically active agent in contact with moist surface,e.g.,eye
US4730013A (en) 1981-10-08 1988-03-08 Merck & Co., Inc. Biosoluble ocular insert
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
CA2131101A1 (en) 1992-05-13 1993-11-25 Louis Desantis Jr. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
WO1995010280A1 (en) 1993-10-13 1995-04-20 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
WO1995015958A1 (en) * 1993-12-08 1995-06-15 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
JP3805360B2 (ja) 1994-01-24 2006-08-02 アラーガン、インコーポレイテッド α▲下２Ａ▼アドレナリン受容体作動剤としての芳香族２−アミノ−イミダゾール誘導体
JPH07277979A (ja) 1994-04-12 1995-10-24 Asahi Chem Ind Co Ltd 過粘性症候群治療または予防剤
US5602143A (en) 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5798380A (en) 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy

Also Published As

Publication number Publication date
JP3719609B2 (ja) 2005-11-24
PT868186E (pt) 2005-05-31
DE69634414T2 (de) 2005-11-17
AU720326B2 (en) 2000-05-25
ES2238702T3 (es) 2005-09-01
JP2001509780A (ja) 2001-07-24
KR19990076580A (ko) 1999-10-15
US6403590B1 (en) 2002-06-11
EP0868186A1 (de) 1998-10-07
MX9805033A (es) 1998-09-30
AU1464497A (en) 1997-07-17
CN1207680A (zh) 1999-02-10
US6271224B1 (en) 2001-08-07
HK1015691A1 (en) 1999-10-22
DE69634414D1 (de) 2005-04-07
WO1997023222A1 (en) 1997-07-03
KR100452715B1 (ko) 2004-12-17
CN1155383C (zh) 2004-06-30
TW534814B (en) 2003-06-01
EP0868186B1 (de) 2005-03-02

Similar Documents

Publication Publication Date Title
ATE289815T1 (de) Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
Krachmer Pellucid marginal corneal degeneration
DK112190A (da) Prostaglandinderivater til behandling af glaukom eller foroeget okulaert tryk
ATE286880T2 (de) Verwendung von fluprostenolisopropylester zur herstellung eines arzneimittels zur behandlung von glaukom und okularer hypertension
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
FR2411821A1 (fr) Nouveaux 1,9-dihydroxyoctahydrophenanthrenes et 1-hydroxyoctahydrophenanthrene-9-ones et medicament les contenant
DE3872701D1 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
DE69930271D1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
AU4672300A (en) Biochemical methods that eliminate corneal scars, opacification and haze
DE69534620D1 (de) Verfahren zur behandlung von augenerkrankungen
Davenport et al. Loss of sight following snake bite
DE69829062D1 (de) Verwendung von flunarizin zur topischen behandlung ocularem hochdruck
ATE213634T1 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
EP0345028A3 (de) Verwendung eines Phosphodiesterase-Inhibitors zur Glaukombehandlung
KR930019214A (ko) 안과용 아르가트로반 제제
SU1342500A1 (ru) Способ лечени глаукомы
CA2240271A1 (en) Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
RU2120281C1 (ru) Способ подготовки мягких контактных линз к применению
SU1544385A1 (ru) Способ хирургического лечени глазных заболеваний, обусловленных ишемией зрительного нерва
SU1251898A1 (ru) Способ лечени птоза верхнего века
RU94028835A (ru) Способ дозированной хирургической коррекции смешанного астигматизма
Sakimoto et al. Decrease of anterior ciliary arterial pressure with increased ocular pressure.
RU96124676A (ru) Способ хирургического лечения осложненных форм отслоек сетчатки
RU97113443A (ru) Способ лечения ожогов глаз
O’Reilly Gormaz, A. and Eggers, C. Scheie’s op-eration for glaucoma. Arch. chil. de oftal. 16: 25-31, Jan.-June, 1959. The author describes his experience with Scheie’s operation which consists of

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0868186

Country of ref document: EP

REN Ceased due to non-payment of the annual fee